Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau(Centre Hospitalier Universitaire de Nantes), Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht(Kyiv City Clinical Oncology Center), Xavier Leleu(Hôpital Claude Huriez), Maria Grishunina(Nizhny Novgorod Regional Clinical Hospital named after Semashko), Grigoriy Rekhtman(Khmelnytskyi National University), Zvenyslava Masliak(Institute of Blood Pathology and Transfusion Medicine of the National Academy of Medical Sciences of Ukraine), Tadeusz Robak(Medical University of Lodz), A. V. Shubina(City Clinical Hospital), Bertrand Arnulf(Hôpital Saint-Louis), Martin Kropff(University of Münster), James Cavet(The Christie NHS Foundation Trust), Dixie‐Lee Esseltine(Millennium Engineering and Integration (United States)), Huaibao Feng(Johnson & Johnson (United States)), Suzette Girgis(Johnson & Johnson (United States)), Helgi van de Velde(Janssen (Belgium)), William Deraedt(Janssen (Belgium)), Jean‐Luc Harousseau(Institut Génétique Nantes Atlantique)
Cited by 917
Abstract
Related Papers
No related papers found
Powered by citation graph analysis